Laevoroc Oncology Unveils Immunology Subsidiary with CSO Shanta Bantia to Develop PNP Inhibitor for Eradication of Relapsed Leukemia
Zug, Switzerland, 7 July 2021: Laevoroc Oncology (‘Laevoroc’ or ‘the company’), a privately-owned, Swiss oncology development company, announced today the appointment of Shanta Bantia, PhD, as CSO of Laevoroc Immunology, an asset-centric subsidiary of Laevoroc, developing a highly potent Purine Nucleoside Phosphorylase (PNP) inhibitor, LR 09 (Ulodesine), to guide the immune system to eradicate relapsed leukemia after stem cell transplantation.
